IP Verse

Combination Therapy Of Substituted Oxazolidinones - EP2099453

The patent EP2099453 was granted to Bayer on Sep 6, 2017. The application was originally filed on Oct 19, 2007 under application number EP07819133A. The patent is currently recorded with a legal status of "Revoked".

EP2099453

BAYER
Application Number
EP07819133A
Filing Date
Oct 19, 2007
Status
Revoked
Sep 16, 2022
Grant Date
Sep 6, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVA GROUPMar 19, 2021ELLIS -
HEXAL SANDOZJun 6, 2018LEDERER & KELLERADMISSIBLE
HEXAL SANDOZJun 6, 2018LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
KRAUS & WEISERT PATENTANWALTE PARTGMBBJun 6, 2018GERAUERADMISSIBLE
STADA ARZNEIMITTELJun 6, 2018KERNEBECKADMISSIBLE
INTERQUIMJun 6, 2018FERRER INTERNACIONALWITHDRAWN
DENK PHARMAJun 5, 2018STRYCHADMISSIBLE
MEDICHEMJun 5, 2018ABG LAWADMISSIBLE
ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETIJun 4, 2018BREUERADMISSIBLE
GENERICS UKJun 4, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTDE10129725
INTERNATIONAL-SEARCH-REPORTWO2006045756
OPPOSITIONCA2451258
OPPOSITIONCA2668068
OPPOSITIONDE10129725
OPPOSITIONDK2099453T
OPPOSITIONEP1411932
OPPOSITIONEP1427415
OPPOSITIONUS2004067995
OPPOSITIONUS2004242660
OPPOSITIONUS5989578
OPPOSITIONWO03000256
OPPOSITIONWO03026652
OPPOSITIONWO2004031143
OPPOSITIONWO2006045756
OPPOSITIONWO2006103206
OPPOSITIONWO2008052671
OPPOSITIONWO9729753
OTHERUS2004242660
OTHERWO2008052671

Non-Patent Literature (NPL) Citations (47) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- KUBITZA DAGMAR; BECKA MICHAEL; MUECK WOLFGANG; ZUEHLSDORF MICHAEL, "Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin", JOURNAL OF CLINICAL PHARMACOLOGY, (200609), vol. 46, no. 9, pages 981 - 990, XP009098173 [Y] 1-11 * abstract * * page 986, column L, line 2 - page 988, column L, line 31 * * page 989, lines 15-23 * * figures 3-6; tables 1,2 *-
INTERNATIONAL-SEARCH-REPORT- COMMIT (CLOPIDOGREL AND METOPROLOL IN MYOCARDIAL INFARCTION TRIAL) COLLABORATIVE GROUP, "Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial", LANCET THE, LANCET LIMITED. LONDON, GB, (20051105), vol. 366, no. 9497, ISSN 0140-6736, pages 1607 - 1621, XP005149889 [A] 1-11 * the whole document *
OPPOSITION- A.S. MANOLIS et al., "Aspirin and Clopidogrel: A Sweeping Combination in Cardiology", Curr. Med. Chem. - Cardiovascular & Hemato- logical Agents, (20050000), vol. 3, pages 203 - 219, XP055494418-
OPPOSITION- BERENBAUM et al., "Synergy, additivism and antagonism in immunosuppression", Clin. Exp. Immunol., (19770000), vol. 28, no. 1, pages 1 - 18, XP055246276-
OPPOSITION- BRAUNWALD. E. et al., "ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines...", Circulation, (20021001), vol. 106, no. 14, pages 1893 - 1900, XP055497078-
OPPOSITION- "Chapter 38- Principles of Combination Chemotherapy", David E. Golan, Armen H. Tashijan et al.,, Principles of Pharmacology: Phe Pathophysiologic Basis of Drug Therapy, Lippincott Willams & Wilkins, (20050000), page 2pp, 605, XP055497061-
OPPOSITION- "Chapter 60 & 61", Alan D. Michelson, Platelets, Second Edition, Academic Press, (20070000), pages 1099 - 1144, XP055497031-
OPPOSITION- COMMIT (CLOPIDOGREL AND METOPROLOL IN MYOCARDIAL INFARCTION TRIAL) COLLABORATIVE GROUP, "Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial", LANCET,, (20051105), vol. 366, no. 9497, pages 1607 - 1621, XP027764707-
OPPOSITION- COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial); collaborative group, "Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial", The Lancet, (20051105), vol. 366, pages 1607 - 1621, XP027764707-
OPPOSITION- "Drug interaction", Wikipedia, the free encyclopedia, (20180516), pages 1 - 14, URL: https://en.wikipedia.org/wiki/Drug_interaction, XP055512792-
OPPOSITION- E. PERZBORN et al., Concomitant administration of low-dose riva- roxaban - an oral, direct factor Xa inhibitor - with clopidogrel and acetylsalicylic acid enhances antithrombotic efficacy in rats-
OPPOSITION- European Medicines Agency (EMA), "Plavix", Summary of Product Characteristics, (20060901), pages 1 - 13, XP055497311-
OPPOSITION- Experimental data submitted by the Applicant during the examination proceedings of the contested patent ;-
OPPOSITION- HERBERT et al., "The Antiaggregating and Antithrombotic Activity of Clopidogrel Is Potentiated by Aspirin in Several Experimental Models in the Rabbit", Thromb. Haemost., (19980000), vol. 80, pages 512 - 518, XP002949864-
OPPOSITION- Jean-Marc Herbert, Frédérique Dol, André Bernat, Robert Falotico, Alain Lalé, Pierre Savi, "The Antiaggregating and Antithrombotic Activity of Clopidogrel Is Potentiated by Aspirin in Several Experimental Models in the Rabbit", Thrombosis and Haemostasis, (19980901), vol. 80, no. 3, pages 512 - 518, XP055497034-
OPPOSITION- JNEID et al., "Aspirin and Clopidogrel in Acute Coronary Syndrome", Archives of Internal Medicine, (20030000), vol. 163, pages 1145 - 1153, XP055495066-
OPPOSITION- K. MOSHFEGH et al., "antiplatelet effects og clopidogrel comared with aspirin after myocardial infarction enhanced inhibitory effects of combination therapy", Journal of the American College of Cardiology, (20000000), vol. 36, no. 3, pages 699 - 705, XP055494407-
OPPOSITION- Kubitza Dagmar; Becka Michael; Mueck Wolfgang; Zuehlsdorf Michael, "Safety , Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin", J. Clin. Pharmacol., (20060901), vol. 46, no. 9, pages 981 - 990, XP009098173-
OPPOSITION- KUBITZA D et al., "Safety , Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban--an Oral, Direct Factor Xa Inhibitor --Are Not Affected by Aspirin", Clin Pharmacol., (20060900), vol. 46, no. 9, pages 981 - 990, XP009098173-
OPPOSITION- Kubitza et al., "Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - Are Not Affected by Aspirin", J Clin Pharmacol, (20060000), vol. 46, no. 9, pages 981 - 990, XP009098173-
OPPOSITION- KUBITZA et al., "Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin", J. Clin. Pharmacol., (20060000), vol. 46, no. 9, pages 981 - 990, XP009098173-
OPPOSITION- KUBITZA et al., "Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factorXa inhibitor - are not affected by aspirin", J Clin Pharmacol, (20060901), vol. 46, no. 9, pages 981 - 990, XP009098173-
OPPOSITION- KUBITZA et al., "Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Riva- roxaban - an Oral, Direct Factor Xa Inhibitor - Are Not Affected by Aspirin", Journal of Clinical Pharmacology, (20060000), vol. 46, no. 9, pages 981 - 990, XP009098173-
OPPOSITION- MANOLIS et al., "Aspirin and clopidogrel: A sweeping combination in Cardiology", Curr Med Chem, Cardiovascular & Hematological Agents, (20050000), vol. 3, pages 203 - 219, XP055494418-
OPPOSITION- M. A. PACKHAM et al., "Clinical Pharmacology of Platelets", Blood, (19771000), vol. 50, no. 4, pages 555 - 573, XP055512784-
OPPOSITION- Marc S. Sabatine, Et Al.,, "Addition of Clopidogrel to Aspirin and Fibrinolytic Therapyfor Myocardial Infarction with ST-Segment Elevation", N Engl J Med, (20050324), vol. 352, no. 12, pages 1179 - 1189, XP055497045-
OPPOSITION- MOSHFEGH et al., "Antiplatelet Effects of Clopidogrel Compared With Aspirin After Myocardial Infarction: Enhanced Inhibitory Effects of Combination Therapy", Journal of the American College of Cardiology, (20000000), vol. 36, no. 3, pages 699 - 705, XP055494407-
OPPOSITION- Perzborn E, "Concomitant administration of low-dose rivaroxaban -an oral, direct Factor Xa inhibitor- with clopidogrel and acetylsalicylic acid enhances antithrombotic efficacy in rats", European Society of Cardiology (ESC) Congress,, (20090101), XP055495077-
OPPOSITION- PERZBORN et al., "Concomitant administration of low-dose rivaroxaban - an oral, direct Factor Xa inhibitor - with clopidogrel and acetylsalicylic acid enhances antithrombotic efficacy in rats", European Society of Cardiology (ESC) Congress, Barcelona, (20090000), XP055495077-
OPPOSITION- "Section I General Principles", Joel G. Hardman, Lee E. Limbird, Alfred Goodman Gilman, Goodman & Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw-hill, (20010000), page 2pp, 72, XP055497064-
OPPOSITION- "Synergist (Pharmakologie)", Wikipedia, the free encyclopedia, (20150914), URL: https://de.wikipedia.org/wiki/Synergist_(Pharmakologie), XP055512795-
OPPOSITION- The OASIS-6 Trial Group, "Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial", JAMA, (20060405), vol. 295, no. 13, pages 1519 - 1530, XP055497297-
OPPOSITION- World Health Organization, "Proposed International Nonproprietary Names: List 93", WHO Drug Information, (20050000), vol. 19, no. 2, page 101, 163, XP055497074-
OPPOSITION- YUSUF, S et al., "Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes", The New England Journal of Medicine, (20060314), vol. 354, no. 14, pages 1464 - 1476, XP055497083-
OPPOSITION- Z. CHEN et al., "Addition of clopidogrel to aspirin in 45 852 patients with actue myocardial infarction randomised placebo-controlled traial", Lancet, (20050000), vol. 366, pages 1607 - 1621, XP055494411-
OPPOSITION- Z.M. CHEN et al., "Addition of clopidogrel to aspirin in 45,852 pa- tients with acute myocardial infarction: randomised placebo- controlled trial", Lancet, (20050000), vol. 366, pages 1607 - 1621, XP055494411-
OPPOSITION- FOUCQUIER et al., "Analysis of drug combinations: current methodological landscape", Pharmacology Research & Perspectives, (20150000), vol. 3, no. 3, pages 1 - 11, XP055462926
OPPOSITION- DAYKIN et al., "Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat", Thrombosis Research, (20060000), vol. 118, no. 6, pages 755 - 762, XP005841261
OPPOSITION- "Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial", COMMIT group, (20051105), vol. 366, no. 9497, ISSN 0140-6736, pages 1607 - 1621, XP005149889
OPPOSITION- SHAKER A. MOUSA, "Antiplatelet therapies: from aspirin to GPIIb/llla-receptor antagonists and beyond", Reviews Therapeutic Focus, (19991200), vol. 4, no. 12, XP000908981
OPPOSITION- Anonymous, "Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation", The New England Journal of Medicine, - NEJM -, (20010816), vol. 345, no. 7, pages 494 - 502, XP055497039
OPPOSITION- Gesine Dörr, Gunter Schmidt, Michael Gräfe, Vera Regitz-Zagrosek, Eckart Fleck, "Effects of Combined Therapy With Clopidogrel and Acetylsalicylic Acid on Platelet Glycoprotein Expression and Aggregation", Journal of Cardiovascular Pharmacology, (20020401), vol. 39, no. 4, pages 523 - 532, XP055497025
OPPOSITION- Ting-Ting Hong, Jinbao Huang, Edward Driscoll, Benedict R Lucchesi, "The Antithrombotic Effect of Melagatran in Combination With Clopidogrel and/or Aspirin (carotid artery primary thrombosis study)", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, (20051001), vol. 46, no. 4, pages 526 - 533, XP055497302
OPPOSITION- E. PERZBORN et al., "In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor", Journal of Thrombosis and Haemostasis, (20050300), vol. 3, no. 3, pages 514 - 521, XP009050814
OPPOSITION- D. R. PHILLIPS et al., "JOURNAL OF THROMBOSIS AND HAEMOSTASIS", Journal of Thrombosis and Haemostasis, (20050000), vol. 3, pages 1577 - 1589, XP055494415
OPPOSITION- PETERS RJ et al., "Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study", Circulation, (20031007), vol. 108, no. 14, pages 1682 - 1687, XP055512788
OPPOSITION- KUBITZA D; HAAS S, "Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases", Expert Opinion on Investigational Drugs,, (20060801), vol. 15, no. 8, pages 843 - 855, XP002410709

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents